Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Study of ASP1941 - Open-label, Non-comparative Study to Assess the Long-term Safety, Tolerability and Efficacy of ASP1941 in Combination With a Dipeptidyl Peptidase-4 Inhibitor in Japanese Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control With a Dipeptidyl Peptidase-4 Inhibitor Alone

NCT01242228 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT01242228
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01242228 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Study of ASP1941 - Open-label, Non-comparative Study to Assess the Long-term Safety, Tolerability and Efficacy of ASP1941 in Combination With a Dipeptidyl Peptidase-4 Inhibitor in Japanese Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control With a Dipeptidyl Peptidase-4 Inhibitor Alone
Lead sponsor
Astellas Pharma Inc
Phase
Phase 3
Overall status
Completed
Start date
October 21, 2010
Completion date
June 6, 2012
Enrollment
106 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus